WebNov 29, 2024 · Strattera (atomoxetine) is a non-stimulant medication used to treat attention-deficit hyperactivity disorder (ADHD) in children and adults. Most side effects are mild and should go away after your body adjusts to the medication. The most common side effects of Strattera include nausea, dry mouth, and headaches. A lower appetite is also possible. WebNov 29, 2024 · Strattera (atomoxetine) is a non-stimulant medication used to treat attention-deficit hyperactivity disorder (ADHD) in children and adults. Most side effects are mild …
Atomoxetine (Strattera) for attention deficit hyperactivity disorder
WebThis is a great way to manage any type of side effect but it’s especially helpful for those that cause anxiety or tension. Conclusion. Atomoxetine is generally well-tolerated and has few side effects, but it may cause low blood pressure, dizziness, dry mouth, nausea, or … WebAug 2, 2024 · Strattera (Atomoxetine) received an overall rating of 5 out of 10 stars from 383 reviews. See what others have said about Strattera (Atomoxetine), including the effectiveness, ease of use and side effects. ... My most significant side effect during that time was insomnia. east barge
Strattera Overview: How It Works and Side Effects to Know - Health
WebFeb 10, 2011 · Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders of childhood and adolescence. Classically, stimulants have been used in the treatment of this condition. Atomoxetine (Strattera; Eli Lilly and Company) is a selective norepinephrine reuptake inhibitor (SNRI), one of the first medications in the … WebApr 27, 2024 · Suppressed appetite. Menstrual cramps and/or irregular periods in women. Strattera can cause severe side effects, although it is rare. Severe side effects include: Chest pain. Aggression. Hallucinations. Increased blood pressure (blurred vision, severe headaches) Numbness or burning/tingling feeling in the skin. WebFeb 27, 2024 · CYP2D6 genotype has a great impact on atomoxetine exposure, where our real-world data suggest atomoxetine dose requirements to be around half and 1/10 in CYP2D6 IM and PM vs. NM patients, respectively. When adding CYP2C19 genotype as a factor of relevance for personalized atomoxetine dosing, CYP2C19*2 carriers should … cuba football players